CVS Health Corporation (CVS)
Health Care7 articles
Price chart
CVS Health Corporation (CVS) overview
CVS Health operates retail pharmacies, a pharmacy-benefits manager, and the Aetna insurance business. It is a member of the S&P 500 and is classified in the Health Care sector — pharmaceutical, biotech, device and managed-care companies.
CVS Health Corporation trades on the NYSE under the ticker symbol CVS. As of the most recent market data, the stock was priced around $107.47, up 0.91% on the session, giving CVS Health Corporation a market capitalization of roughly $137.12B.
Over the past 52 weeks, CVS has traded between $58.50 and $108.97. Shares are valued at a trailing price-to-earnings (P/E) ratio of about 46.7, a common gauge of how richly the market prices the company's earnings. CVS Health Corporation also pays a dividend, currently yielding around 2.50%.
Key statistics
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch CVS
As one of the larger companies in the Health Care sector, CVS Health Corporation is closely followed by investors and often moves with broader trends across pharmaceutical, biotech, device and managed-care companies. Traders watch CVS for earnings reports, analyst rating changes, and headlines that can shift sentiment — each of which is summarized on this page as it breaks.
Because the S&P 500 is weighted by market value, CVS Health Corporation's size means its share-price moves can also nudge the index as a whole, making CVS a stock that even index investors pay attention to.
Market Mood
Latest CVS news
CVS (CVS) Reports 3% Net Income Margin, $100.4 Billion Revenue
CVS Health (CVS) reported a net income margin of approximately 3% for Q1 2026, generating $100.4 billion in revenue, with $32 billion from retail pharmacy sales. UnitedHealth (UNH) achieved a 6% net income margin for the same period, reporting $111.7 billion in revenue and a 2% increase from 2025. Both companies project positive growth, having raised their full-year guidance. The comparison highlights divergent business models and revenue trends, positioning both firms as potential investments in the healthcare sector.
Read More: CVS (CVS) Reports 3% Net Income Margin, $100.4 Billion Revenue
BlackRock Boosts CVS Group (CVS) Stake to 5% Ownership
BlackRock has increased its stake in CVS Group (CVS) to 5%. This move indicates BlackRock's confidence in CVS's long-term prospects. The increase may impact CVS's stock performance positively, as institutional interest can lead to enhanced market stability. Investors will be monitoring CVS for further developments in relation to this stake acquisition.
Read More: BlackRock Boosts CVS Group (CVS) Stake to 5% Ownership
BlackRock Stake in CVS (CVS) Falls Below 5% Amid Market Changes
BlackRock's ownership in CVS Group (CVS) has dropped below 5%. This reduction in stake may lead to changes in investor perception and stock dynamics. Institutional interest in CVS remains a key factor for market stability. Such a decline in ownership could potentially influence trading volumes and share price.
Read More: BlackRock Stake in CVS (CVS) Falls Below 5% Amid Market Changes
CVS (CVS) Restores Coverage of Zepbound, Adds Eli Lilly's Foundayo
CVS Health (CVS) announced the restoration of coverage for Eli Lilly's (LLY) Zepbound effective October 1 and will add the Foundayo obesity pill on June 1. This adjustment positions Lilly to compete equally with Novo Nordisk in the weight loss market, affecting an estimated 25 million to 30 million Americans. CVS aims for a 10% to 15% increase in savings across weight management treatments with the updated formulary. The decision follows a prior agreement with Novo Nordisk that made Wegovy the favored choice on CVS plans while previously excluding Zepbound.
Read More: CVS (CVS) Restores Coverage of Zepbound, Adds Eli Lilly's Foundayo
CVS Health (CVS) Stock Price Target Raised on Margin Recovery
Mizuho has increased the stock price target for CVS Health (CVS) due to anticipated margin recovery. This revision signifies confidence in the company's ability to improve profitability, which could have a positive effect on its share price. The adjustment reflects ongoing market assessments regarding CVS's performance and operational efficiency. Analysts' price targets are significant indicators of expected market movements and investor sentiment.
Read More: CVS Health (CVS) Stock Price Target Raised on Margin Recovery
Market Outlook: Earnings Week Ahead for Major Techs and AMD
Jim Cramer indicated that the previous earnings week showed positive results for major tech companies but cautioned that upcoming reports may be challenging. Companies like Advanced Micro Devices (AMD) and Eaton are expected to report strong quarters, with Cramer recommending buying AMD ahead of its earnings. Data center demand, particularly in the context of AI expansion, remains crucial for market performance. Additionally, the labor market is evolving, with artificial intelligence driving productivity and fewer hires, which could have significant implications for Federal Reserve policy.
Read More: Market Outlook: Earnings Week Ahead for Major Techs and AMD
US Health Insurers Surge on Medicare Payments Increasing 2.48%
US health insurers, including Humana (HUM), UnitedHealth Group (UNH), and CVS Health (CVS), saw their stocks rise following a Medicare Advantage payment increase. The Centers for Medicare & Medicaid Services (CMS) announced a net average increase of 2.48% in payments for 2027, up from a previously proposed 0.9%. This adjustment is projected to add approximately $13 billion in revenue to private insurers. The higher payments are aimed at providing financial relief amid rising medical costs, with Humana shares rising 6.4%, UnitedHealth by 8.8%, and CVS by 6.6%.
Read More: US Health Insurers Surge on Medicare Payments Increasing 2.48%More Health Care stocks
Frequently asked questions
Is CVS Health Corporation in the S&P 500?
Yes. CVS Health Corporation (CVS) is a member of the S&P 500 index, classified in the Health Care sector.
What sector is CVS in?
CVS Health Corporation is classified in the Health Care sector of the S&P 500 — pharmaceutical, biotech, device and managed-care companies.
Where can I find the latest CVS news?
This page collects recent CVS Health Corporation (CVS) news and market analysis, each article summarized by AI and tagged with bullish, bearish, or neutral sentiment.
What is CVS Health Corporation's stock price?
As of the most recent market data, CVS Health Corporation (CVS) traded at approximately $107.47. Prices move throughout the trading day, so this reflects the latest available quote rather than a live price.
What is CVS Health Corporation's market cap?
CVS Health Corporation has a market capitalization of roughly $137.12B, based on its most recent share price and shares outstanding.
What is CVS's P/E ratio?
CVS trades at a trailing price-to-earnings ratio of about 46.7. The P/E ratio compares a company's share price to its earnings per share.